Sign in

Private company

REGENEREX PHARMA, INC.

REGENEREX PHARMA, INC. is an American pharmaceutical preparations company, incorporated in Nevada.1 It is headquartered in Las Vegas, Nevada.1

Last updated Oct 21, 2026.

Overview

-$2.5MNet income, fiscal 20252
  • IndustryPharmaceutical Preparations1
  • HeadquartersLas Vegas, Nevada1
  • Incorporated inNV3
  • Business address5348 Vegas Drive, Suite 177, Las Vegas, Nv 891083
  • Filer category, Emerging growth company3

See how the biggest companies compare on our leaderboards

Regenerex Pharma, Inc. (the "Company" or "Regenerex Pharma") specializes in the development and commercialization of advanced wound care healing products. The Company operates through three distinct proprietary technologies designed to address different wound care needs:4 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2021

-13798.1%Gross margin5
-2445.7%Operating margin6
-19929.7%Net margin6
-31.9%Revenue growth, 20215

Where the money goes

Where each dollar of revenue went, fiscal 2021

  • Cost of revenue85¢$246.7K
  • Interest15¢$42.9K

Out of $1.8K in revenue.56 The company lost money this year.

Financial statements

Revenue5$1.8K in 2021−32% since 2020
0$1.0K$2.0K$3.0K2020: $2.6K$2.6K20202021: $1.8K$1.8K2021−32%
Gross profit5-$244.9K in 2021
-$300.0K-$200.0K-$100.0K0$100.0K2020: $896$89620202021: -$244.9K-$244.9K2021
Operating income7856-$43.4K in 2021−12% since 2018
-$100.0K-$75.0K-$50.0K-$25.0K02018: -$49.5K-$49.5K20182019: -$91.7K-$91.7K2019+86%2020: -$77.0K-$77.0K2020−16%2021: -$43.4K-$43.4K2021−44%
Net income7856-$353.8K in 2021+612% since 2018
-$400.0K-$200.0K0$200.0K2018: -$49.7K-$49.7K20182019: -$93.6K-$93.6K2019+88%2020: $111.6K$111.6K20202021: -$353.8K-$353.8K2021
Fiscal year2018201920202021
Revenue$2.6K5$1.8K5
Cost of revenue$1.7K5$246.7K5
Gross profit$8965-$244.9K5
Research and development
Selling, general and admin
Operating expenses
Operating income-$49.5K7-$91.7K8-$77.0K5-$43.4K6
Interest$7788$28.7K5$42.9K6
Income tax
Net income-$49.7K7-$93.6K8$111.6K5-$353.8K6
Shares (weighted, basic)

Compare REGENEREX PHARMA, INC. with another company

What it owns

What REGENEREX PHARMA, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Machinery and equipment$5.6K2 Mar 31, 2025$6.1K2 Mar 31, 2024−8.2%
Accumulated depreciation$3.6K13 Dec 31, 2025$1.6K2 Mar 31, 2024+123.4%
Property and equipment, net$2.5K13 Dec 31, 2025
Operating-lease assets (leased space)$487.0K13 Dec 31, 2025$756.3K2 Mar 31, 2024−35.6%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.0K13 Dec 31, 2025$3722 Mar 31, 2024+2870.2%

Intangibles and goodwill

ItemLatestA year beforeChange
Accumulated amortization$30.6K2 Mar 31, 2025$29.3K2 Mar 31, 2024+4.5%

Properties, in its own words

The Company does not own its own facilities and is presently renting an identity office in Las Vegas, Nevada and corporate office in Gordonsville, TN.

Item 2 of the 10-KT filed Aug 31, 2026.14

Leadership

Who has led REGENEREX PHARMA, INC., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. R. Scott McKinley2013

Chief financial officer

  1. John Erik Odeen2013
201520202025
Board members and other officers (3)

Former names

  • Eternelle Skincare Products Inc.Jun 23, 2017 to Feb 8, 20183
  • PEPTIDE TECHNOLOGIES, INC.Oct 13, 2011 to Dec 22, 20213
  • CREENERGY CorpJun 29, 2010 to Oct 6, 20113
  • ONLINE ORIGINALS, INCApr 18, 2006 to Jul 19, 20103

Timeline

  1. Sep 4, 20268-K Change of auditor18
  2. Sep 1, 20268-K Other events19
  3. Jun 22, 20268-K Other events20
  4. Jun 11, 20268-K Executive or director change21
  5. May 6, 20268-K Executive or director change22
  6. Apr 2, 20268-K Executive or director change23
  7. Nov 12, 20258-K Bylaws or fiscal year changed24
  8. Sep 3, 20258-K Entered a material agreement25
  9. Jul 31, 20258-K Entered a material agreement26
  10. Apr 2, 20258-K Executive or director change27
  11. Dec 10, 20248-K Executive or director change28
  12. Sep 28, 20238-K Other events29
  13. Oct 16, 2013New chief executive R. Scott McKinley becomes CEO15

Filings

39 filings to the SEC since October 2021: 5 annual reports, 14 quarterly reports, 16 major events, 4 other. The latest 20:

  1. Sep 4, 20268-K CURRENT REPORT EDGAR
  2. Sep 1, 20268-K CURRENT REPORT EDGAR
  3. Aug 31, 202610-KT TRANSITION REPORT FOR PERIOD ENDING DECEMBER 31, 2025 EDGAR
  4. Jun 22, 20268-K CURRENT REPORT EDGAR
  5. Jun 11, 20268-K CURRENT REPORT EDGAR
  6. May 6, 20268-K CURRENT REPORT EDGAR
  7. Apr 2, 20268-K CURRENT REPORT EDGAR
  8. Mar 30, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
  9. Nov 17, 202510-Q QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2025 EDGAR
  10. Nov 17, 2025NT 10-Q NOTIFICATION OF LATE FILING EDGAR
  11. Nov 12, 20258-K CURRENT REPORT EDGAR
  12. Sep 3, 20258-K CURRENT REPORT EDGAR
  13. Aug 14, 202510-Q QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2025 EDGAR
  14. Jul 31, 20258-K CURRENT REPORT EDGAR
  15. Jun 30, 202510-K ANNUAL REPORT FOR THE FISCAL YEAR ENDED MARCH 31, 2025 EDGAR
  16. Apr 2, 20258-K CURRENT REPORT EDGAR
  17. Feb 7, 202510-Q QUARTERLY REPORT FOR THE PERIOD ENDED DECEMBER 31, 2024 EDGAR
  18. Dec 10, 20248-K CURRENT REPORT EDGAR
  19. Nov 4, 202410-Q QUARTERLY REPORT FOR THE PERIOD ENDED SEPTEMBER 30, 2024 EDGAR
  20. Aug 7, 202410-Q QUARTERLY REPORT FOR THE PERIOD ENDED JUNE 30, 2024 EDGAR

The 39 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

SEC filer profile

How REGENEREX PHARMA, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARREGENEREX PHARMA, INC.1
  • CIK0001357878
  • Employer ID (EIN)98-047998314
  • Filer statusNon-accelerated filer14
  • Incorporated inNevada14
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address5348 Vegas Drive, Suite 177, Las Vegas, NV 891081
  • Phone305-927-51911
  • Shares outstanding283,157,310 shares as of Aug 25, 202614
  • Public float$0 as of Dec 31, 202513
  • Auditordbbmckennon, Newport Beach, California PCAOB ID 350114
  • On EDGAR sinceApr 18, 20061
  • Filings167 in all: 10-Q (44), 8-K (41), 10-K (15), UPLOAD (11), 10QSB (8), NT 10-Q (8), NT 10-K (7), 10-K/A (4)1
    All 24 form types

    CORRESP (4), 10-Q/A (3), 3 (3), DEF 14C (3), PRE 14C (3), 10-12G/A (2), 10KSB (2), 10-12B (1), 10-12G (1), 10-KT (1), 15-12G (1), 8-A12G (1), 8-K/A (1), PRER14C (1), SB-2 (1), SC 13D (1)

  • Latest filingsAnnual report (10-KT) Aug 31, 2026
    Quarterly report (10-Q) Nov 17, 2025
    Latest 8-K (8-K) Sep 4, 2026

Risk factors and legal proceedings

The risks REGENEREX PHARMA, INC. names in Item 1A of its 10-KT filed Aug 31, 2026: 14 risks under these headings, as written.14

  • The Company will face competition from existing consumer product companies.
  • The Company has a lack of revenue history and has had a limited history of operations.
  • The Company can give no assurance of success or profitability to the Company’s investors.
  • The Company will need additional financing for which it has no commitments, and this may jeopardize the execution of the Company’s business plan.
  • The Company will incur expenses in connection with its Securities and Exchange Commission (SEC) filing requirements and may not be able to meet such costs, which could jeopardize its filing status with the SEC.
  • The Company is not diversified, and it is dependent on only one business.
  • The Company may in the future issue more shares, which could cause a loss of control by its present management and current stockholders.
  • The Company will depend upon its management, but it will have limited participation of management.
  • The departure of key personnel could compromise the Company’s ability to execute its strategic plan and may result in additional severance costs.
  • The Company will need to recruit and retain additional qualified personnel to successfully grow its business.
  • The regulation of penny stocks by the SEC and FINRA may discourage the tradability of the Company’s securities.
  • The Company’s officers and directors collectively own a substantial portion of its outstanding common stock, and as long as they do, they may be able to control the outcome of stockholder voting.
The other 2 risks
  • The Company may seek to raise additional funds or develop strategic relationships by issuing capital stock.
  • The Company will pay no foreseeable dividends in the future.

Legal proceedings

As of December 31, 2025, the Company was not involved in any material litigation.

As of June 11, 2026, the Company filed a lawsuit against its former Chief Financial Officer, Kenneth W. Perry, and, as of June 18, 2026, commenced related legal proceedings against Optimize Health Partners, LLC, a Delaware limited liability company conducting business in Tennessee and owned by Mr. Perry, to recover funds and other amounts alleged to be owed to the Company and to address additional matters arising from his conduct during his tenure. The actions seek monetary damages, restitution, disgorgement where applicable, injunctive relief, costs, and other equitable remedies. The Company is pursuing all available legal and equitable relief, and the allegations remain subject to judicial determination, with no assurance as to the outcome.

The opening of Item 3, Legal Proceedings.14

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
    SEC EDGAROther events
  20. 20
    SEC EDGAROther events
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
    SEC EDGAROther events